share_log

C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Mossler Mark

C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities

C4 Therapeutics | 4：持股變動聲明
美股sec公告 ·  04/10 16:19
Moomoo AI 已提取核心訊息
Mark Mossler, the Chief Accounting Officer of C4 Therapeutics, Inc. (CCCC), completed a stock acquisition on February 14, 2024. The transaction involved a grant of 18,290 shares of common stock at no cost. Following this transaction, Mossler's direct holdings in the company increased to a total of 19,790 shares. The grant is part of the company's compensation structure and reflects the ongoing commitment of the executive to the firm.
Mark Mossler, the Chief Accounting Officer of C4 Therapeutics, Inc. (CCCC), completed a stock acquisition on February 14, 2024. The transaction involved a grant of 18,290 shares of common stock at no cost. Following this transaction, Mossler's direct holdings in the company increased to a total of 19,790 shares. The grant is part of the company's compensation structure and reflects the ongoing commitment of the executive to the firm.
C4 Therapeutics, Inc.（CCCC）的首席會計官馬克·莫斯勒於2024年2月14日完成了股票收購。該交易涉及免費授予18,290股普通股。在這筆交易之後，莫斯勒在該公司的直接持股量增加到總共19,790股。該補助金是公司薪酬結構的一部分，反映了高管對公司的持續承諾。
C4 Therapeutics, Inc.（CCCC）的首席會計官馬克·莫斯勒於2024年2月14日完成了股票收購。該交易涉及免費授予18,290股普通股。在這筆交易之後，莫斯勒在該公司的直接持股量增加到總共19,790股。該補助金是公司薪酬結構的一部分，反映了高管對公司的持續承諾。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息